Pomerantz Investigates Dr. Reddy's Securities Fraud Claims
Analysis based on 9 articles · First reported Aug 25, 2026 · Last updated Sep 10, 2026
The investigation adds legal uncertainty for Abbott Laboratories, potentially leading to further stock price volatility and reputational damage. Broader market impact is limited as this is a company-specific legal matter within the pharmaceutical sector.
Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories Limited regarding potential securities fraud or other unlawful business practices. The investigation stems from Dr. Reddy's announcement on July 22, 2026 of its first quarter fiscal 2027 earnings, which reported earnings per share of only $0.06, adversely impacted by a 2.4 billion rupee provision related to out-of-specification semaglutide batches. CEO Erez Israeli stated that the quarter's EBITDA margin was adversely impacted by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives and other associated costs. Following this news, Dr. Reddy's stock price fell $1.18 per share, or 9.4%, to close at $11.38 per share on July 22, 2026. Pomerantz LLP, a law firm specializing in corporate, securities, and antitrust class litigation, is advising affected investors to contact them regarding potential participation in a class action. The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard